Atopic Dermatitis Market

Atopic Dermatitis Market Overview

The atopic dermatitis market size is projected to grow from USD 13.69 billion in 2025 to USD 31.86 billion by 2035, representing a CAGR of 8.81% during the forecast period till 2035.

To learn more about this report, request a free sample copy

The new research study consists of atopic dermatitis market and trends analysis, detailed market forecast analysis, and provide actionable strategic recommendations.

According to an Oxford Academic report, nearly 2.6% of the population is affected by atopic dermatitis worldwide where children are more affected compared to adults,. This number exhibits a high prevalence of skin conditions similar to eczema that raise the atopic dermatitis market demand. Atopic dermatitis also known as eczema is a chronic inflammatory skin condition. This skin disease can be identified with redness, rash, inflammation, and itchy skin, which are some of the common atopic dermatitis symptoms. The disease can be caused by to combination of factors, such as genetic, immune dysregulation, and environmental factors. With the growing urbanization, pollution, and lifestyle changes, the cases of eczema continue to rise fueling the demand for atopic dermatitis diagnosis which includes clinical examination, medical history, and diagnostic criteria.

As an effect, the atopic dermatitis market is evolving rapidly by providing treatment for the disease that focuses on managing symptoms, reducing inflammation, and repairing the skin barrier through skincare. The ongoing advancements in treatment options, such as biologics drugs, JAK inhibitors, and topical innovations have multiplied the scope of the industry. It is interesting to note that among the available drugs, biologics are the leading segment in terms of revenue. This resulted in several pharmaceutical companies exploring new pathways, such as IL-3, IL-33, and OX40 to develop next-generation treatments. Also, diverse modalities, and atopic dermatitis pipelines such as biologics, small molecules, and topical therapies can offer a wide range of options for patients aiding the market demand.

Moreover, the emerging trends of digital therapeutics are transforming the industry where stakeholders and pharmaceutical companies are leveraging technological advancements by developing digital health solutions for eczema to capitalize on the growing industry demand. For instance, in February 2025, Sibel Health shared a peer-reviewed study in the Journal of American Medical Association (JAMA) Dermatology of its AI-powered wearable technology which tracks and reduces nighttime scratching in mild atopic dermatitis.

Overall, considering these factors, the eczema treatment market is predicted to sprout out substantially. Nevertheless, the high cost of therapies and side effects of the treatments are a few challenges that need to be addressed to maintain the growth rate of the market throughout this forecast period.

Atopic Dermatitis Market Share Insights

The atopic dermatitis market report presents an in-depth analysis of the various companies that are involved in offering atopic dermatitis, across different segments, as defined in the table below:

Atopic Dermatitis Market: Report Attributes / Market Segmentations

Atopic Dermatitis Market Segmentation

Market Share by Type of Drug

This segmentation of the global atopic dermatitis market features different types of drugs wherein biologics are the leading segment and poised to foster the segment growth with (~44%) of the market share till the forecast period. Specifically, IL-4 and IL14 inhibitors drive the segment demand due to their high efficacy in moderated-to-severe cases and reduced systemic side effects. Besides this, corticosteroid drugs are witnessing substantial demand and are expected to register a faster (10.24%) CAGR over this forecast period. Corticosteroids are highly effective at reducing inflammation, redness, and itching. They are easily available in various strengths and formulations such as creams ointments, and lotions, thereby bolstering the segment’s growth.

Market Share by Route of Administration

Based on the route of administration, topical administration is the dominating segment and is projected to occupy (~46%) of the market share by 2035. This is due to the fact that topical treatments are the most widely used route of administration for atopic dermatitis especially, for mild-to-moderate cases. Also, topical treatments are easy to apply and do not require medical supervision. Furthermore, the parenteral route of administration segment is anticipated to grow at a notable (9.56%) CAGR during this projection timeframe. This can be ascribed to the rising demand for injectable therapies, particularly, biologics owing to their high efficacy, chronic management, and targeted therapies.

Market Share by Type of Distribution Channel

The market for atopic dermatitis is segmented into various distribution channels such as hospital pharmacies, retail pharmacies, online pharmacies, and others. According to atopic dermatitis biologics market research, hospital pharmacies are the leading distribution channel for AD treatments, especially, biologics and advanced therapies, and are expected to hold the highest (~49%) of the market share by 2035. The key factor behind this dominance is the complexity of treatment as biologics and systemic therapies often require administration under medical supervision and make hospital pharmacies the primary point of distribution.

Furthermore, retail pharmacies are likely to rise at a faster CAGR of (12.35%) over this forecast period. This growth can be accredited to the accessibility and over-the-counter products such as moisturizers and antihistamines which are available OTC through retail pharmacies.

Market Share by Geographical Regions

This segment highlights the distribution of the atopic dermatitis market across various geographical regions, such as North America, Europe, Asia, Latin America, the Middle East and North Africa, and the rest of the world. With regard to the atopic dermatitis drug market, North America is anticipated to lead the market by holding (~46%) of the market share till the forecast period. Meanwhile, Asia is evolving significantly and is likely to witness (12.84%) growth rate during this forecast period. This growth can be ascribed to the growing cases of atopic dermatitis in Asia. China, India, and South Korea are some of the prominent nations which are experiencing a rise in skin inflammation and eczema cases driven by high pollution, and lifestyle changes coupled with a higher genetic predisposition to atopic dermatitis, contributing to the patient pool.

Also, Asia contains over 60% of the world’s population which makes it a gigantic atopic dermatitis treatment market, focusing on pediatric atopic dermatitis due to having a large pediatric population, supplementing the market demand. Besides this, the expansion of the pharmaceutical industry with both local pharmaceutical companies and global giants is widening the market reach across regions, supporting the market growth in Asia.

Atopic Dermatitis Market Key Insights

The “Atopic Dermatitis Market, Till-2035: Industry Trends and Global Forecasts” report features an extensive study of the current market landscape, market size and future opportunities within the atopic dermatitis market, during the given forecast period. The market report highlights the efforts of several stakeholders involved in this rapidly emerging segment of the service providers industry. Key takeaways of the atopic dermatitis market report are briefly discussed below.

Key Drivers of the Atopic Dermatitis Market

One of the primary key drivers of the atopic dermatitis market growth is the increasing prevalence of atopic dermatitis and skin inflammation around the world. Atopic dermatitis is one of the most common skin conditions in children as well a significant portion of cases persist into adulthood, thus, fostering the market demand for effective long-term treatments. Along with this, continuous advancements in treatment options such as biologics JAK inhibitors, and non-steroidal topicals are spurring market development by reducing the side effects of the targeted therapies. Moreover, increasing awareness of atopic dermatitis and increasing demand for personalized therapies are further expected to expand the market scope in the upcoming years.

Atopic Dermatitis Market Competitive Landscape

Currently, the market is witnessing intense competition with the presence of established pharmaceutical companies and a growing number of biotech firms. Leading companies such as Sanofi and Regeneron Pharmaceuticals, Pfizer, AbbVie, LEO Pharma, Eli and Lily, and others dominate the industry by occupying the majority of the market share. These companies stimulate market growth with their biologics, JAK inhibitors, and other targeted therapies. While merging startups are emphasizing the development of novel treatments, personalized medicine, and expansion into pediatric and adolescent populations.

Market Challenges in Atopic Dermatitis Market

The high cost of advanced therapies such as biologics drugs and JAK inhibitors and safety concerns related to the adverse impact of topical steroids are some of the notable challenges that might slow down the growth of the market. Although, these treatments are effective, yet, long-term use of topical corticosteroids which is a common treatment for mild to moderate atopic dermatitis can cause side effects such as skin thinning and systemic absorption. Additionally, biologics and JAK inhibitors carry the risk of immunosuppression, infections, and other systemic side effects which can curb their use in certain patient populations, and impact the market expansion.

Regional Analysis: North America is Expected to Dominate the Market with the Largest Atopic Dermatitis Market Share

North America is projected to capture (~46%) share of the market and will continue to dominate the global landscape. Particularly, the US market leads significantly due to high atopic dermatitis prevalence in both pediatrics and adults. The US has a substantial patient population suffering from atopic dermatitis which drives the demand for eczema treatments. The growth of the market is also attributed to the advanced healthcare infrastructure and strong adoption of biologics and novel therapies in the region. Additionally, a robust pharmaceutical industry with its R&D for a combination of therapies inducing topical plus systemic, solidifying the region’s leading position in the global marketplace. For instance, in July, The FDA approved Arcutis biotherapeutics’ ZORYVE for atopic dermatitis. This steroid-free once daily cream highlights the importance of PDE4 research in inflammatory disease.

Leading Atopic Dermatitis Manufacturing Companies

Examples of key players involved in the market for atopic dermatitis (which have also been captured in this market report, arranged in alphabetical order) include AbbVie (US), Anacor Pharmaceuticals (US), Bayer (Germany), Eli Lilly and Company (US), Encore Dermatology (US), Galderma Laboratories (Switzerland), Incyte (US), LEO Pharma (Denmark), MedPointe Pharmaceutical (US), Novartis AG (Switzerland), Otsuka Pharmaceutical (Japan), Pfizer (US), Regeneron Pharmaceuticals (US), and Sanofi (France). This market report includes an easily searchable excel database of all the companies who have adopted the atopic dermatitis market.

Recent Developments in Atopic Dermatitis Market

• In May 2024, ASLAN Pharmaceutical extended its partnership with Zenyaku Kogyo Co to study eblasakimab’s mechanism of action in atopic dermatitis, comparing it with dupilumab (Dupixent) and lebrikizumab.
• In April 2024, the FDA accepted Dermavant Science’s sNDA for VTAMA (tapinarof) cream, 1% to treat atopic dermatitis in adults and children 2 years of age.
• In January 2024, Pfizer teaming up with Glenmark Pharma introduced abrocitinib, an oral advanced systematic treatment for moderate-to-severe atopic dermatitis in India.

Atopic Dermatitis Market Report Coverage

The market report presents an in-depth analysis, highlighting the capabilities of various companies engaged in this domain, across different segments. Amongst other elements, the market report includes:

• A preface providing an introduction to the full report atopic dermatitis market, 2020-2024 (Historical Trends) and till-2035 (Forecasted Estimates).
• An outline of the systematic research methodology adopted to conduct the study on the atopic dermatitis market providing insights on the various assumptions, methodologies, and quality control measures employed to ensure the accuracy and reliability of our findings.
• An overview of economic factors that impact the overall atopic dermatitis market including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the insights captured during our research. It offers a high-level view on the current state of the atopic dermatitis market their likely evolution in the mid-long term.
• A detailed assessment of the atopic dermatitis market landscape, based on several relevant parameters, including year of experience, company size, location of headquarters, and ownership structure.
• Elaborate profiles of prominent players engaged in the atopic dermatitis market, featuring information on their year of establishment, location of headquarters, company size, company mission, company footprint, management team, contact details, financial information, operating business segments, atopic dermatitis market portfolio, moat analysis, recent developments, and an informed future outlook.
• A qualitative assessment of the various megatrends ongoing in the atopic dermatitis industry, including increasing emphasize on non-steroidal topical treatments and rising adoption of digital health solutions .
• An analysis highlighting the key unmet needs across the atopic dermatitis market, featuring insights generated from real-time data on unmet needs as identified from social media posts, recent publications, industry blogs and the views of key opinion leaders expressed on online platforms.
• An in-depth analysis of various patents that have been filed / granted related to atopic dermatitis market and its components, based on various parameters, such as type of patent, patent publication year, patent age and leading players.
• A detailed analysis of recent developments in the atopic dermatitis market domain, based on relevant parameters such as year of initiative, type of initiative (partnerships and collaborations, expansions, funding and product launches), geographical distribution and most active players (in terms of number of recent developments).
• Key winning strategies framework that helps in analyzing the level of competition within an industry, by tracing the key market activities including partnership, funding, expansion of leading players
• A qualitative analysis, highlighting the five competitive forces prevalent in atopic dermatitis market, including threats for new entrants, bargaining power of suppliers, bargaining power of customers, threats of substitution and rivalry among existing competitors.
• A discussion on affiliated global atopic dermatitis market trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall atopic dermatitis market.
• A value chain analysis featuring a discussion on various stakeholders involved in the development of the atopic dermatitis market, from suppliers to end-users.
• A detailed estimate of the current market size and the future growth potential of the atopic dermatitis market over the next decade. Based on multiple parameters we have provided an informed estimate on the market evolution during the forecast period 2025-2035. The report also features the likely distribution of the current and forecasted opportunity within the atopic dermatitis market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base, and optimistic scenarios, representing different tracks of the industry’s growth.
• Detailed projections of the current and future market across various types of drugs such as calcineurin inhibitors, corticosteroids, PDE4 inhibitors, and others.
• Detailed projections of the current and future market across various types of routes of administration such as oral, parenteral, and topical.
• Detailed projections of the current and future market across various types of distribution channels such as hospital pharmacies, retail pharmacies, and others.
• Detailed projections of the current and future atopic dermatitis market across various geographical regions, such as North America (US, Canada, Mexico and other North American countries), Europe (Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Russia, Spain, Sweden, Switzerland, UK and other European countries), Asia (China, India, Japan, Singapore, South Korea and other Asian countries), Middle East and North Africa (Egypt, Iran, Iraq, Israel, Kuwait, Saudi Arabia, UAE and other MENA countries), Latin America (Brazil, Chile, Colombia, Venezuela and other Latin American countries) and rest of the world (Australia, New Zealand and other countries).

Author: Ronit Sharma and Neha Kashyap